# Data Sheet (Cat.No.T30506)

TargetMol

BMS-212122

## Chemical Properties



CAS No. : 194213-64-4

Formula: C43H36F6N4O2

Molecular Weight: 754.76

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

## Biological Description

| | |
|---|---|
| Description | BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques. |
| Targets(IC50) | MTP |

## Solubility Information

| | |
|---|---|
| Solubility | DMSO: 50 mg/mL (66.25 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.3249 mL | 6.6246 mL | 13.2492 mL |
| 5 mM | 0.265 mL | 1.3249 mL | 2.6498 mL |
| 10 mM | 0.1325 mL | 0.6625 mL | 1.3249 mL |
| 50 mM | 0.0265 mL | 0.1325 mL | 0.265 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hewing B, et al. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013 Mar;227 (1):125-9.
Robl JA, et al. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001 Mar 15;44(6):851-6.
Peled M, et al. A wild-type mouse-based model for the regression of inflammation in atherosclerosis. PLoS One. 2017;12(3):e0173975.